Immunological Medicine最新文献

筛选
英文 中文
Progressive multifocal leukoencephalopathy associated with obinutuzumab-bendamustine: combination therapy with mirtazapine and immunoglobulin. 进行性多灶性白质脑病与本纽单抗-苯达莫司汀:米氮平和免疫球蛋白联合治疗。
IF 2.3
Immunological Medicine Pub Date : 2026-11-12 DOI: 10.1080/25785826.2026.2760587
Yohei Takenobu, Kazuo Nakamichi, Kayoko Yukawa, Mari Inoue, Karen Hatano, Yuki Hama, Keita Mochida, Mizuha Toyama, Junichi Miyahara, Kentaro Yamakawa, Manabu Inoue
{"title":"Progressive multifocal leukoencephalopathy associated with obinutuzumab-bendamustine: combination therapy with mirtazapine and immunoglobulin.","authors":"Yohei Takenobu, Kazuo Nakamichi, Kayoko Yukawa, Mari Inoue, Karen Hatano, Yuki Hama, Keita Mochida, Mizuha Toyama, Junichi Miyahara, Kentaro Yamakawa, Manabu Inoue","doi":"10.1080/25785826.2026.2760587","DOIUrl":"https://doi.org/10.1080/25785826.2026.2760587","url":null,"abstract":"<p><p>Progressive multifocal leukoencephalopathy (PML) is a severe opportunistic infection of the central nervous system resulting from JC virus (JCV) reactivation, often leading to substantial neurological morbidity and mortality. While associated with various immunotherapies, the incidence of PML specifically following obinutuzumab-bendamustine as first-line therapy remains under-reported. We aim to highlight this potent regimen as a trigger for JCV reactivation and evaluate therapeutic strategies. We describe a patient who presented with cognitive decline two years after completing obinutuzumab-bendamustine therapy for follicular lymphoma, accompanied with profound lymphopenia and hypogammaglobulinemia. A diagnosis of PML was established based on deep white matter lesions on brain MRI and a positive cerebrospinal fluid (CSF) polymerase chain reaction for JCV. Treatment consisted of daily mirtazapine together with intravenous immunoglobulin (IVIG) supplementation. At the 2-year follow-up, the patient demonstrated sustained radiological stabilization, cognitive improvement, and undetectable JCV viral load in CSF. Obinutuzumab-bendamustine therapy represents a distinct clinical trigger for PML due to its dual-arm immunosuppressive effects on humoral and cellular immunity. While endogenous cellular immune restoration likely played a primary role in viral clearance, adjunctive mirtazapine and IVIG may represent a feasible supportive strategy, particularly following B-cell-depleting therapy. The therapeutic contribution of this combined regimen requires further investigation.</p>","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-6"},"PeriodicalIF":2.3,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149411585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of fluorescein staining with the yellow filter in the diagnosis of Sjögren disease in Japan. 黄色滤光片荧光素染色在日本Sjögren疾病诊断中的价值评价。
IF 2.3
Immunological Medicine Pub Date : 2026-11-04 DOI: 10.1080/25785826.2026.2738347
Toshimasa Shimizu, Kazumi Shinozaki, Susumu Nishiyama, Hideki Nakamura, Masafumi Moriyama, Naoto Azuma, Hiroto Tsuboi, Masafumi Uematsu, Masakazu Yamada, Atsushi Kawakami
{"title":"Evaluation of fluorescein staining with the yellow filter in the diagnosis of Sjögren disease in Japan.","authors":"Toshimasa Shimizu, Kazumi Shinozaki, Susumu Nishiyama, Hideki Nakamura, Masafumi Moriyama, Naoto Azuma, Hiroto Tsuboi, Masafumi Uematsu, Masakazu Yamada, Atsushi Kawakami","doi":"10.1080/25785826.2026.2738347","DOIUrl":"https://doi.org/10.1080/25785826.2026.2738347","url":null,"abstract":"<p><p>Sjögren disease (SjD) requires ocular surface assessment during diagnostic evaluation. In Japan, the 1999 revised Japanese Ministry of Health criteria include the van Bijsterveld score based on the Rose Bengal test; however, this test is rarely performed in current clinical practice. Although fluorescein staining with the yellow filter is widely used as an alternative method, its performance for suspected SjD remains unclear. To clinically evaluate this method, this multicenter retrospective study included 400 patients who underwent fluorescein staining with the yellow filter for suspected SjD between 2010 and 2024. Expert clinical diagnosis served as the reference diagnosis, with 322 being diagnosed with SjD and 78 classified as non-SjD. At a cutoff value ≥3 for the van Bijsterveld score using fluorescein staining with the yellow filter, sensitivity was 48.4% and specificity 84.6%, with a positive predictive value of 92.9%. At a cutoff value ≥4, sensitivity was 32.6% and specificity 93.6%, with a positive predictive value of 95.5%. After replacing the Rose Bengal test in the 1999 criteria with fluorescein staining with the yellow filter, the modified criteria showed 86.6% sensitivity, 93.6% specificity, and 88.0% accuracy. Fluorescein staining with the yellow filter may be a practical ocular assessment method for suspected SjD.</p>","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-10"},"PeriodicalIF":2.3,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149325611","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful treatment of refractory myositis-associated interstitial lung disease with an interleukin-6 inhibitor: four-patient case series. 白介素-6抑制剂成功治疗难治性肌炎相关间质性肺疾病:4例病例系列
IF 2.3
Immunological Medicine Pub Date : 2026-11-04 DOI: 10.1080/25785826.2026.2753878
Chihiro Imaizumi, Reina Maezawa, Yasuto Minegishi, Takehisa Ogura, Hideto Kameda
{"title":"Successful treatment of refractory myositis-associated interstitial lung disease with an interleukin-6 inhibitor: four-patient case series.","authors":"Chihiro Imaizumi, Reina Maezawa, Yasuto Minegishi, Takehisa Ogura, Hideto Kameda","doi":"10.1080/25785826.2026.2753878","DOIUrl":"https://doi.org/10.1080/25785826.2026.2753878","url":null,"abstract":"<p><strong>Objectives: </strong>Myositis-associated interstitial lung disease (ILD) is a potentially fatal disease, despite combination therapy with glucocorticoids (GC) and other immunosuppressive agents. New therapies, including biologics targeting relevant cytokines, such as interleukin (IL)-6, are warranted. We retrospectively reviewed patients with myositis-associated ILD who were treated with the IL-6 inhibitor tocilizumab (TCZ) to determine the clinical usefulness of TCZ.</p><p><strong>Methods: </strong>Four patients with myositis-associated ILD treated with TCZ between 2019 and 2023 were identified from the records of our medical centre.</p><p><strong>Results: </strong>All patients were female, aged 43-84 years. One patient was positive for the antimelanoma differentiation-associated gene 5 antibody, while the others were positive for anti-aminoacyl-tRNA synthetase antibodies. All patients met the classification criteria for rheumatoid arthritis. The initial GC dose was 1 mg/kg/day (40-60 mg/day) of prednisolone, and GC-pulse therapy was administered to all but one patient. TCZ treatment was initiated within 6 months of the initial treatment. All patients showed clinical and radiological improvements after TCZ therapy, achieving GC reduction or withdrawal. The Warrick score, which semi-quantitatively evaluates ILD, improved from a median of 14.5 (moderate) to 4 (mild). Furthermore, no relapse or serious adverse events were observed.</p><p><strong>Conclusion: </strong>TCZ is a potential treatment option for refractory myositis-associated ILD.</p>","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-9"},"PeriodicalIF":2.3,"publicationDate":"2026-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149335471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Longitudinal changes in gut microbial evenness and dominance during anti-CD20-containing chemoimmunotherapy with concurrent trimethoprim-sulfamethoxazole prophylaxis in patients with B-cell lymphoma. b细胞淋巴瘤患者抗cd20化学免疫治疗联合甲氧苄啶-磺胺甲恶唑预防期间肠道微生物均匀性和优势度的纵向变化
IF 2.3
Immunological Medicine Pub Date : 2026-10-29 DOI: 10.1080/25785826.2026.2753278
Shun Ito, Shimon Otake, Masaru Nakagawa, Hiromichi Takahashi, Katsuhiro Miura, Hideki Nakamura, Shihoko Komine-Aizawa
{"title":"Longitudinal changes in gut microbial evenness and dominance during anti-CD20-containing chemoimmunotherapy with concurrent trimethoprim-sulfamethoxazole prophylaxis in patients with B-cell lymphoma.","authors":"Shun Ito, Shimon Otake, Masaru Nakagawa, Hiromichi Takahashi, Katsuhiro Miura, Hideki Nakamura, Shihoko Komine-Aizawa","doi":"10.1080/25785826.2026.2753278","DOIUrl":"https://doi.org/10.1080/25785826.2026.2753278","url":null,"abstract":"<p><p>Reduced gut microbial diversity is associated with adverse outcomes in hematological malignancies. However, longitudinal studies during lymphoma chemoimmunotherapy rarely distinguish richness from evenness. We investigated whether microbial diversity shifts during anti-CD20-containing chemoimmunotherapy reflect loss of detected taxa or redistribution of relative abundances. In this prospective, single-center exploratory study, 40 patients with B-cell lymphoma provided pretreatment stool samples and 18 paired post-treatment samples. All 18 participants received trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis from treatment initiation through post-treatment sampling, without additional systemic antibacterial exposure between collections or during the 3 months preceding baseline. Following 16S rRNA gene V3-V4 sequencing, Pielou's evenness (<i>q</i> = 0.0077) and Shannon diversity (<i>q</i> = 0.0208) decreased post-treatment, whereas observed features and Faith's phylogenetic diversity did not change significantly (<i>q</i> = 0.4923 and 0.7660, respectively). Dominance significantly increased (Simpson, <i>q</i> = 0.0154; Berger-Parker, <i>q</i> = 0.0237). Beta diversity showed no detectable compositional shift, no genus-level taxon met differential-abundance criteria, and newly dominant taxa varied across individuals. These changes accompanied the combined treatment exposure in a cohort that may overrepresent clinically stable patients; the chemoimmunotherapy and TMP-SMX contributions were inseparable. These alterations appear modest and predominantly structural, with the clearest changes in evenness and dominance, and substantial uncertainty about richness.</p>","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-16"},"PeriodicalIF":2.3,"publicationDate":"2026-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149300889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Altered plasma metabolomic profiles in treatment-naïve patients with newly diagnosed rheumatoid arthritis. 新诊断的类风湿性关节炎treatment-naïve患者血浆代谢组学特征的改变
IF 2.3
Immunological Medicine Pub Date : 2026-10-07 DOI: 10.1080/25785826.2026.2739140
Miwa Kanaji, Junko Nishio, Mayuko Oka, Keiko Koshiba, Kaori Motomura, Shotaro Masuoka, Mai Kawazoe, Eri Watanabe, Sei Muraoka, Kaichi Kaneko, Karin Furukawa, Izumi Irita, Zento Yamada, Takehiko Sugihara, Toshihiro Nanki
{"title":"Altered plasma metabolomic profiles in treatment-naïve patients with newly diagnosed rheumatoid arthritis.","authors":"Miwa Kanaji, Junko Nishio, Mayuko Oka, Keiko Koshiba, Kaori Motomura, Shotaro Masuoka, Mai Kawazoe, Eri Watanabe, Sei Muraoka, Kaichi Kaneko, Karin Furukawa, Izumi Irita, Zento Yamada, Takehiko Sugihara, Toshihiro Nanki","doi":"10.1080/25785826.2026.2739140","DOIUrl":"https://doi.org/10.1080/25785826.2026.2739140","url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) is characterized by chronic inflammatory polyarthritis. Despite recent advances in treatment, a subset of patients remains refractory, highlighting the need for better biomarkers for diagnosis and disease activity monitoring to determine appropriate interventions. Therefore, this study aimed to characterize the plasma metabolic profiles of RA and identify candidate metabolite markers for the disease. Plasma samples from treatment-naïve patients with newly diagnosed RA (<i>n</i> = 48) and healthy controls (HC; <i>n</i> = 45) were analyzed using liquid chromatography-tandem mass spectrometry. Fifty-five metabolites were included in the analysis; carnosine, glutamic acid, dimethylglycine, and taurine were significantly increased in RA, whereas histidine, methionine sulfoxide, tryptophan, and alanine were significantly decreased. Metabolite set enrichment analysis showed altered histidine metabolism in patients with RA, and the carnosine/histidine ratio showed the highest area under the ROC curve among the metabolites tested. Histidine was also inversely associated with disease activity and anti-citrullinated protein antibody (ACPA) production. In addition, decreased citrulline levels were significantly associated with higher ACPA production. This study identified the carnosine/histidine ratio as a candidate marker for RA and implicates an imbalance between carnosine synthesis and degradation in its pathophysiology, based on an analysis of treatment-naïve patients with covariate adjustments.</p>","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-16"},"PeriodicalIF":2.3,"publicationDate":"2026-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Age-dependent myositis-specific autoantibody profiles and CD8+ T-cell signatures in juvenile dermatomyositis. 青少年皮肌炎中年龄依赖性肌炎特异性自身抗体谱和CD8+ t细胞特征
IF 2.3
Immunological Medicine Pub Date : 2026-09-29 DOI: 10.1080/25785826.2026.2736348
Sungyeon Park, Motoshi Sonoda, Nobutaka Harada, Shunichi Adachi, Keishiro Kinoshita, Yutaro Yada, Katsuhide Eguchi, Motoko Yamanaka, Yuki Ichimura, Naoko Okiyama, Masataka Ishimura, Shouichi Ohga
{"title":"Age-dependent myositis-specific autoantibody profiles and CD8<sup>+</sup> T-cell signatures in juvenile dermatomyositis.","authors":"Sungyeon Park, Motoshi Sonoda, Nobutaka Harada, Shunichi Adachi, Keishiro Kinoshita, Yutaro Yada, Katsuhide Eguchi, Motoko Yamanaka, Yuki Ichimura, Naoko Okiyama, Masataka Ishimura, Shouichi Ohga","doi":"10.1080/25785826.2026.2736348","DOIUrl":"https://doi.org/10.1080/25785826.2026.2736348","url":null,"abstract":"<p><p>Juvenile dermatomyositis (JDM) is an autoimmune myopathy with skin manifestations, yet biomarkers reflecting disease activity and organ involvement at presentation remain incompletely defined. This study aimed to identify clinical and immunologic indicators at diagnosis, focusing on myositis-specific autoantibodies (MSAs) and lymphocyte subsets. We retrospectively analyzed 36 patients with JDM treated at a tertiary center in Japan between 2003 and 2024. MSAs (anti-TIF1-γ, anti-MDA5, anti-NXP2, anti-Mi-2, anti-Jo-1, anti-ARS, and anti-SAE) were assessed at diagnosis. Clinical features, laboratory data, and lymphocyte profiles by flow cytometry were compared across MSA subtypes. The cohort (25 females) showed a bimodal age distribution with peaks at 4 and 10 years. Anti-Jo-1 and anti-TIF1-γ antibodies predominated in younger patients, whereas anti-NXP2 was more frequent in older children. Patients with ILD had higher anti-MDA5 positivity (adjusted <i>p</i> = 0.005) and KL-6 levels (adjusted <i>p</i> = 0.007). Both absolute and age-normalized CD8<sup>+</sup> T-cell levels were higher in patients with subcutaneous calcinosis (adjusted <i>p</i> = 0.012 for both). Age-dependent MSA profiles characterize JDM. Anti-MDA5 antibodies were associated with ILD, whereas higher age-normalized CD8<sup>+</sup> T-cell levels were associated with calcinosis, suggesting their potential utility for risk stratification at diagnosis.</p>","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-12"},"PeriodicalIF":2.3,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149076106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical and scintigraphic improvement of mandibular involvement associated with chronic nonbacterial osteitis following an interleukin-23 inhibitor: a case-based literature review. 应用白细胞介素-23抑制剂治疗慢性非细菌性骨炎后下颌受累的临床和影像学改善:一项基于病例的文献综述
IF 2.3
Immunological Medicine Pub Date : 2026-09-25 DOI: 10.1080/25785826.2026.2739130
Koji Suzuki, Mitsuhiro Akiyama, Koichi Saito, Hiroshi Takei, Yuko Kaneko
{"title":"Clinical and scintigraphic improvement of mandibular involvement associated with chronic nonbacterial osteitis following an interleukin-23 inhibitor: a case-based literature review.","authors":"Koji Suzuki, Mitsuhiro Akiyama, Koichi Saito, Hiroshi Takei, Yuko Kaneko","doi":"10.1080/25785826.2026.2739130","DOIUrl":"https://doi.org/10.1080/25785826.2026.2739130","url":null,"abstract":"<p><p>Chronic nonbacterial osteitis (CNO) occasionally presents with severe and refractory mandibular involvement, conventionally called as diffuse sclerosing osteomyelitis. While conventional treatments such as bisphosphonates and tumor necrosis factor (TNF) inhibitors are utilized, optimal management remains challenging due to heterogeneous responses. Here, we report a 59-year-old male with CNO associated with palmoplantar pustulosis who developed refractory mandibular osteitis. Following recurrent relapses under conventional therapies, he was treated with guselkumab, an interleukin (IL)-23 inhibitor. His clinical symptoms and abnormal tracer uptake on bone scintigraphy markedly improved within three months without any adverse events. Furthermore, we conducted a case-based literature review to evaluate the effectiveness of potential therapies, such as IL-17/IL-23 inhibitors and Janus kinase (JAK) inhibitors, for CNO-associated mandibular involvement. The review identified five additional cases treated with these agents. Clinical improvement was observed across all cases, while radiological progression was noted in two patients treated with JAK inhibitors. Although the precise immunopathogenesis of mandibular CNO requires further elucidation, our findings suggest that IL-23, IL-17, and JAK inhibitors may be potential therapeutic options, particularly for patients experiencing treatment failure or paradoxical reactions to conventional biologic agents.</p>","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-9"},"PeriodicalIF":2.3,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149041148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Successful combination therapy with ustekinumab and intensive granulocyte and monocyte adsorptive apheresis in highly refractory pediatric ulcerative colitis: pathophysiological rationale and clinical outcome. ustekinumab与强化粒细胞和单核细胞吸附采珠术成功联合治疗高度难治性儿童溃疡性结肠炎:病理生理原理和临床结果
IF 2.3
Immunological Medicine Pub Date : 2026-09-24 DOI: 10.1080/25785826.2026.2737046
Norito Tsutsumi, Shigeo Nishimata, Miki Eto Tanaka, Yu Kamei, Shun Watanabe, Naoko Saito, Yasuyo Kashiwagi, Tadashi Ichimiya, Masakatsu Fukuzawa, Gaku Yamanaka
{"title":"Successful combination therapy with ustekinumab and intensive granulocyte and monocyte adsorptive apheresis in highly refractory pediatric ulcerative colitis: pathophysiological rationale and clinical outcome.","authors":"Norito Tsutsumi, Shigeo Nishimata, Miki Eto Tanaka, Yu Kamei, Shun Watanabe, Naoko Saito, Yasuyo Kashiwagi, Tadashi Ichimiya, Masakatsu Fukuzawa, Gaku Yamanaka","doi":"10.1080/25785826.2026.2737046","DOIUrl":"https://doi.org/10.1080/25785826.2026.2737046","url":null,"abstract":"<p><p>Pediatric-onset ulcerative colitis (UC) is characterized by an aggressive phenotype, with higher rates of pancolitis and more rapid progression to a medically refractory state. After failure of conventional therapies and multiple biologic agents, treatment options are limited and often require surgery. We report the case of a 15-year-old girl with a 5-year history of highly refractory pancolitis-type UC. Previous treatments included mesalazine, salazosulfapyridine, tacrolimus, and three biologic agents (infliximab, vedolizumab, and adalimumab), all of which failed to maintain remission. After ustekinumab initiation, she initially experienced mild improvement but subsequently developed a severe clinical relapse (Pediatric Ulcerative Colitis Activity Index score: 40-50) triggered by <i>Edwardsiella tarda</i> infection. Despite infection resolution and treatment with systemic corticosteroids, her condition remained critical. As adjunctive therapy, intensive granulocyte and monocyte adsorptive apheresis (GMA) was administered twice weekly for 10 sessions, followed by twice monthly for 7 sessions, resulting in rapid symptomatic improvement. Follow-up colonoscopy confirmed complete mucosal healing (Mayo Endoscopic Subscore, 0). Intensive GMA may be a safe and effective adjunct to ustekinumab before its full therapeutic effect is achieved, potentially complementing the anti-inflammatory effects of ustekinumab in refractory pediatric UC and may help avoid colectomy even when multiple drug therapies have failed.</p>","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-11"},"PeriodicalIF":2.3,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149041227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Leukopenia and thrombocytopenia in immunoglobulin G4-related disease: frequency, severity, and the association with splenomegaly. 免疫球蛋白g4相关疾病中的白细胞减少和血小板减少:频率、严重程度及其与脾肿大的关系
IF 2.3
Immunological Medicine Pub Date : 2026-09-22 DOI: 10.1080/25785826.2026.2735524
Kojiro Ikeda, Shunichiro Hanai, Soichiro Kubota, Nakako Tanaka-Mabuchi, Mayu Yazaki, Yoshiaki Kobayashi, Daiki Nakagomi
{"title":"Leukopenia and thrombocytopenia in immunoglobulin G4-related disease: frequency, severity, and the association with splenomegaly.","authors":"Kojiro Ikeda, Shunichiro Hanai, Soichiro Kubota, Nakako Tanaka-Mabuchi, Mayu Yazaki, Yoshiaki Kobayashi, Daiki Nakagomi","doi":"10.1080/25785826.2026.2735524","DOIUrl":"https://doi.org/10.1080/25785826.2026.2735524","url":null,"abstract":"<p><p>Hematological abnormalities are not generally considered characteristic of immunoglobulin (Ig)G4-related disease (IgG4-RD). This study investigated the frequencies of leukopenia and thrombocytopenia in IgG4-RD and the clinical factors associated with their development. We retrospectively analyzed 56 patients diagnosed with IgG4-RD between April 2015 and July 2024 according to the 2020 revised comprehensive diagnostic criteria. Clinical characteristics were compared between patients with and without thrombocytopenia and splenomegaly. Independent factors associated with thrombocytopenia were evaluated using binomial logistic regression. Leukopenia and thrombocytopenia occurred in 6 (10.7%) and 24 (42.8%) patients, respectively. Marked thrombocytopenia (platelet count <10.0 × 10<sup>4</sup>/μL) was observed in 11 patients (19.6%). Patients with thrombocytopenia were older, more often male, and more likely to have splenic and aortic involvements, with significantly higher serum IgG levels. Splenomegaly was associated with increased frequencies of leukopenia and thrombocytopenia, as well as lower platelet and lymphocyte counts. Multivariate analysis identified older age as consistently associated with thrombocytopenia, while splenomegaly was independently associated with thrombocytopenia and marked thrombocytopenia in selected models. Most patients treated with glucocorticoids showed improved blood cell counts within 12 weeks. Thrombocytopenia may be common in IgG4-RD, and splenomegaly and older age are associated with thrombocytopenia.</p>","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-11"},"PeriodicalIF":2.3,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149025666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploratory analysis of IFN-α-high and CXCL9-high cytokine distributions in systemic lupus erythematosus-associated macrophage activation syndrome. 系统性红斑狼疮相关巨噬细胞激活综合征中IFN-α-高和cxcl9 -高细胞因子分布的探索性分析
IF 2.3
Immunological Medicine Pub Date : 2026-09-22 DOI: 10.1080/25785826.2026.2735585
Shuya Kaneko, Maho Hatano, Asami Shimbo, Futaba Miyaoka, Tomoya Kaneda, Yuko Akutsu, Yuko Hayashi, Tadashi Hosoya, Masae Watanabe, Shotaro Suzuki, Mao Mizuta, Shinsuke Yasuda, Masaaki Mori, Masatoshi Takagi, Masaki Shimizu
{"title":"Exploratory analysis of IFN-α-high and CXCL9-high cytokine distributions in systemic lupus erythematosus-associated macrophage activation syndrome.","authors":"Shuya Kaneko, Maho Hatano, Asami Shimbo, Futaba Miyaoka, Tomoya Kaneda, Yuko Akutsu, Yuko Hayashi, Tadashi Hosoya, Masae Watanabe, Shotaro Suzuki, Mao Mizuta, Shinsuke Yasuda, Masaaki Mori, Masatoshi Takagi, Masaki Shimizu","doi":"10.1080/25785826.2026.2735585","DOIUrl":"https://doi.org/10.1080/25785826.2026.2735585","url":null,"abstract":"<p><p>Macrophage activation syndrome (MAS) is a life-threatening hyperinflammatory complication of systemic lupus erythematosus (SLE), but its immunopathology remains poorly understood. We investigated cytokine-associated inflammatory heterogeneity in SLE-associated MAS (SLE-MAS). Serum levels of interferon (IFN)-α, C-X-C motif chemokine ligand 9 (CXCL9), interleukin (IL)-6, IL-18 and soluble TNF receptor type II (sTNF-RII) were measured in nine patients with SLE-MAS and compared with patients with systemic juvenile idiopathic arthritis-associated MAS (sJIA-MAS), Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) and healthy controls. Exploratory principal component analysis (PCA) was performed to visualize cytokine patterns. Patients with SLE-MAS exhibited elevated IFN-α levels, whereas IL-6 and IL-18 levels were lower than those in sJIA-MAS and EBV-HLH. Exploratory PCA suggested descriptive IFN-α-high and CXCL9-high cytokine distributions. Patients with the IFN-α-high pattern tended to have leukopenia and lupus nephritis, whereas those with the CXCL9-high pattern showed higher LDH levels and HScore values. IFN-α levels were associated with leukopenia but were not significantly correlated with SLEDAI-2K scores. These exploratory findings suggest that SLE-MAS may exhibit heterogeneous IFN-α-high and CXCL9-high cytokine distributions. These observations should be interpreted as descriptive, and hypothesis-generating rather than as validated biological subtypes or a treatment-stratification tool.</p>","PeriodicalId":37286,"journal":{"name":"Immunological Medicine","volume":" ","pages":"1-8"},"PeriodicalIF":2.3,"publicationDate":"2026-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149018141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书